Naparstek E, Shinar E, Polliack A
Isr J Med Sci. 1984 Feb;20(2):118-22.
Eleven patients with acute leukemia, refractory to all previous chemotherapy, were treated with acridinyl anisidide (m-AMSA). Seven patients received m-AMSA i.v. as a single agent at 150 mg/m2 daily for 4 to 7 days, and 4 patients received m-AMSA at 90 mg/m2 daily for 3 days in combination with thioguanine and cytosine arabinoside. Four of the nine patients with acute nonlymphoblastic leukemia responded to the treatment, and complete remission was obtained in three of them. One of these patients remained in complete remission 5 months after therapy. Three of the four responding patients received m-AMSA as a single agent. Two patients with resistant acute lymphoblastic leukemia did not respond. As in earlier trials with m-AMSA reported by others, about one-third of our refractory patients responded, which justifies the future use of this agent in refractory leukemia and in other regimens for the induction of remission in acute leukemia. Despite minimal cardiotoxicity of the drug, evidence of its cardiotoxic potential is recorded.
11例对既往所有化疗均耐药的急性白血病患者接受了吖啶基茴香胺（m-AMSA）治疗。7例患者静脉注射m-AMSA作为单一药物，剂量为150mg/m²，每日1次，共4至7天；4例患者接受m-AMSA，剂量为90mg/m²，每日1次，共3天，并联合硫鸟嘌呤和阿糖胞苷。9例急性非淋巴细胞白血病患者中有4例对治疗有反应，其中3例获得完全缓解。其中1例患者在治疗后5个月仍处于完全缓解状态。4例有反应的患者中有3例接受m-AMSA作为单一药物治疗。2例耐药的急性淋巴细胞白血病患者无反应。正如其他人之前报道的关于m-AMSA的试验一样，我们约三分之一的难治性患者有反应，这证明该药物未来可用于难治性白血病以及其他诱导急性白血病缓解的方案。尽管该药物心脏毒性极小，但仍有其潜在心脏毒性的记录。
